NDAINJECTIONINJECTABLE
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OPTIRAY 300 (ioversol) by Guerbet is x-ray contrast activity [moa]. First approved in 1988.
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 300 (ioversol) is an injectable radiographic contrast agent used to enhance visualization during X-ray imaging procedures. It works through X-ray contrast activity to improve image clarity in diagnostic imaging. The drug is administered via injection and has been a standard diagnostic tool since 1988.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature franchise requiring defensive strategies and potential team restructuring.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OPTIRAY 300 offers limited career growth opportunity given the mature lifecycle and approaching LOE with minimal linked job openings. Positions available are primarily defensive commercial roles focused on market maintenance and competitive pricing rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on OPTIRAY 300 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.